These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 3902545)

  • 1. New developments in the incretin concept.
    Creutzfeldt W; Ebert R
    Diabetologia; 1985 Aug; 28(8):565-73. PubMed ID: 3902545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes.
    Nauck MA; Baller B; Meier JJ
    Diabetes; 2004 Dec; 53 Suppl 3():S190-6. PubMed ID: 15561910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Physiology and pathology of the entero-insular axis].
    Creutzfeldt W
    Schweiz Med Wochenschr; 1985 Jul; 115(29):970-3. PubMed ID: 3901250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.
    Nauck MA; Bartels E; Orskov C; Ebert R; Creutzfeldt W
    J Clin Endocrinol Metab; 1993 Apr; 76(4):912-7. PubMed ID: 8473405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Entero-insular axis and diabetes mellitus.
    Creutzfeldt W
    Horm Metab Res Suppl; 1992; 26():13-8. PubMed ID: 1490680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overview of incretin hormones.
    Efendic S; Portwood N
    Horm Metab Res; 2004; 36(11-12):742-6. PubMed ID: 15655702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gastric inhibitory polypeptide analogues: do they have a therapeutic role in diabetes mellitus similar to that of glucagon-like Peptide-1?
    Holst JJ
    BioDrugs; 2002; 16(3):175-81. PubMed ID: 12102645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enteroinsular signaling: perspectives on the role of the gastrointestinal hormones glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide in normal and abnormal glucose metabolism.
    Vahl T; D'Alessio D
    Curr Opin Clin Nutr Metab Care; 2003 Jul; 6(4):461-8. PubMed ID: 12806222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice.
    Hansotia T; Drucker DJ
    Regul Pept; 2005 Jun; 128(2):125-34. PubMed ID: 15780432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disturbances of the entero-insular axis.
    Creutzfeldt W; Ebert R; Nauck M; Stöckmann F
    Scand J Gastroenterol Suppl; 1983; 82():111-9. PubMed ID: 6356314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Gluco-incretin hormones in insulin secretion and diabetes].
    Thorens B
    Med Sci (Paris); 2003; 19(8-9):860-3. PubMed ID: 14593618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucagon-like peptide-1 and control of insulin secretion.
    Thorens B
    Diabete Metab; 1995 Dec; 21(5):311-8. PubMed ID: 8586147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incretin hormones: Their role in health and disease.
    Nauck MA; Meier JJ
    Diabetes Obes Metab; 2018 Feb; 20 Suppl 1():5-21. PubMed ID: 29364588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin.
    Gault VA; O'Harte FP; Harriott P; Mooney MH; Green BD; Flatt PR
    Diabetologia; 2003 Feb; 46(2):222-30. PubMed ID: 12627321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The ageing entero-insular axis.
    Ranganath L; Sedgwick I; Morgan L; Wright J; Marks V
    Diabetologia; 1998 Nov; 41(11):1309-13. PubMed ID: 9833938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.
    Vilsbøll T; Krarup T; Sonne J; Madsbad S; Vølund A; Juul AG; Holst JJ
    J Clin Endocrinol Metab; 2003 Jun; 88(6):2706-13. PubMed ID: 12788877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gastric inhibitory polypeptide: the neglected incretin revisited.
    Meier JJ; Nauck MA; Schmidt WE; Gallwitz B
    Regul Pept; 2002 Jul; 107(1-3):1-13. PubMed ID: 12137960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic stimulatory effect of glucagon-like peptide-1 (7-36) amide and glucose-dependent insulin-releasing polypeptide on the endocrine rat pancreas.
    Fehmann HC; Göke B; Göke R; Trautmann ME; Arnold R
    FEBS Lett; 1989 Jul; 252(1-2):109-12. PubMed ID: 2668027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incretin hormones--an update.
    Holst JJ; Orskov C
    Scand J Clin Lab Invest Suppl; 2001; 234():75-85. PubMed ID: 11713984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preservation of incretin activity after removal of gastric inhibitory polypeptide (GIP) from rat gut extracts by immunoadsorption.
    Ebert R; Unger H; Creutzfeldt W
    Diabetologia; 1983 Jun; 24(6):449-54. PubMed ID: 6350081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.